Skip to content

Released Mar 29, 2019, after the close

10-K filed Apr 1, 2019, 91 days after period end · 0001564590-19-010253

Q4 2018 · 10-K
Revenue$19.09M+372.4% vs Q4 2017+143.6% vs Q3 2018
Net Income-$1.49MN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.07N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$3,275,000—
Operating Cash Flowderived-$5,935,000N/M
Free Cash Flowderived-$6,733,000N/M
Margins · derived
Operating margin-17.2%
Net margin-7.8%+372.0 pt vs Q4 2017

What the release said

The release

Same quarter

MetricQ4 2018Q4 2017
Revenue$19.09M$4.04M
Net Income-$1.49M-$15.34M
EPS Diluted-$0.07-$33.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR